Brief: Ocumension Therapeutics Approves Acquisition Of Suzhou Xiaxiang
11/09/2020 13:51
Sept 11 (Reuters) - Ocumension Therapeutics 1477.HK :
* APPROVED ACQUISITION OF SUZHOU XIAXIANG
* DEAL FOR RMB36 MILLION
Source text for Eikon: ID:nHKS9RG1QF
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application